Syndax Pharmaceuticals, Inc.
NASDAQ:SNDXBiotechnology
+$0.13 today
- Market cap
- $770.64M
- Beta
- 0.39
- P/E (TTM)
- -6.8
- EPS (TTM)
- -$2.81
Volume 3.46M
Average 1.70M
SNDX Total Debt
Short-term and long-term borrowings combined.
Syndax Pharmaceuticals, Inc.NASDAQ: SNDX
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt rises 18700.2% from a year ago
Total debt stood at $345.36M at the end of Q1 FY2026, up 18700.2% from a year earlier and down 0.3% from the prior quarter. Over 3 fiscal years it compounded at +568.3% a year.
Context
- Total debt amounted to 73.1% of total assets at the end of Q1 FY2026, up 72.8 pp from a year earlier.
- Total debt increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps rising in the next quarterly balance sheet after a +18700.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 346.48M USD
- Year-over-year change
- +0.2%
- 4-year CAGR
- +101.6%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 346.48M | +0.2% |
| FY2024 | 2024-12-31 | 345.74M | +21046.1% |
| FY2023 | 2023-12-31 | 1.64M | +40.8% |
| FY2022 | 2022-12-31 | 1.16M | -94.5% |
| FY2021 | 2021-12-31 | 20.97M | — |
Total Debt vs competitors
How SNDX compares with its peers on the latest reported figures
- SNDX's Mar 2026 total debt of $345.36M is the 2nd highest of the 11 companies compared; the peer median is $65.27M.
- Its year-over-year change of +18700.2% is the highest of 11, against a peer median of +1.5%.
- Total debt amounts to 73.1% of total assets for SNDX, versus a peer median of 10.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $662.71M | +3405.7% | -13.4% | 56.3% | |
| Mar 2026 | $345.36M | +18700.2% | +568.3% | 73.1% | |
| Jun 2026 | $252.14M | +336.5% | +33.5% | 33.9% | |
| Jun 2026 | $114M | +4.6% | -2.3% | 12.3% | |
| Dec 2025 | $76.35M | +0.4% | +32.4% | 22.9% | |
| Aug 2026 | $65.33M | +15.7% | +67.0% | 5.5% | |
| Jun 2026 | $65.21M | -4.0% | +46.6% | 9.0% | |
| Mar 2026 | $36.51M | -2.6% | +45.3% | 16.8% | |
| Mar 2026 | $5.22M | -47.7% | -20.6% | 2.9% | |
| Mar 2026 | $3.3M | +2.6% | -1.5% | 0.8% | |
| Mar 2026 | $2.86M | -65.0% | -38.3% | 0.8% | |
| Peer median (excluding SNDX) | $65.27M | +1.5% | +15.4% | 10.7% | |
Competitors are the stored peer set for SNDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 221.97M | 74.36M | 295.39M | 154.08M | 134.93M |
| Short-term Investments | 224.87M | 410.04M | 282.19M | 428.83M | 278.76M |
| Net Receivables | 429K | 4.06M | 1.23M | 13.87M | 70.29M |
| Inventory | 0 | 0 | 0 | 366K | 32.75M |
| Other Current Assets | 265K | 117K | 63K | (2.02M) | 1.22M |
| Total Current Assets | 448.4M | 489.79M | 580.88M | 603.06M | 528.08M |
| Property, Plant & Equipment (Net) | 1.26M | 1.06M | 1.5M | 2.02M | 1.52M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 5.47M | 29.83M | 119.52M | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 922K | 680K | 217K | 102K |
| Total Non-current Assets | 1.26M | 7.45M | 32M | 121.76M | 1.63M |
| Total Assets | 449.66M | 497.24M | 612.88M | 724.82M | 529.71M |
| Account Payables | 5.67M | 4.35M | 9.96M | 11.63M | 16.58M |
| Short-term Debt | 0 | 0 | 0 | 12.12M | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 6.23M | 6.55M | 35.92M | 15.75M | 103.06M |
| Total Current Liabilities | 20.68M | 29.07M | 58.1M | 103.55M | 120.12M |
| Long-term Debt | 19.9M | 0 | 0 | 331.57M | 344.96M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | (1.05M) |
| Total Non-current Liabilities | 20.61M | 722K | 588K | 333.14M | 344.96M |
| Total Liabilities | 41.29M | 29.79M | 58.68M | 436.69M | 465.08M |
| Common Stock | 6K | 7K | 8K | 9K | 9K |
| Retained Earnings | (543.7M) | (693.04M) | (902.4M) | (1.22B) | (1.51B) |
| Accumulated OCI | 45K | (806K) | 218K | 163K | 452K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 408.37M | 467.45M | 554.2M | 288.12M | 64.63M |
| Total Debt | 20.97M | 1.16M | 1.64M | 345.74M | 346.48M |
| Net Debt | (201M) | (73.2M) | (293.76M) | 191.66M | 211.55M |
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
Intrinsic Alpha fair value
Locked
Current Price
$8.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.